A phase III open label study controlled by vitamin D3 supplementation and the differences between young adults and senior population

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519747-15-00

Acronym

D3-2024

Enrollment

150

Registered

2025-03-05

Start date

2025-09-15

Completion date

Unknown

Last updated

2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy population

Brief summary

Primary end point is Serum 25 hydroxycholecalciferol.

Detailed description

Secondary end points are Serum 24,25-dihydroxycholecalciferol levels and Serum 3-epi-25-hydroxycholecalciferol levels.

Interventions

DRUGVigantol 0

DRUG5 mg/ml perorální kapky

DRUGroztok

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary end point is Serum 25 hydroxycholecalciferol.	—

Secondary

Measure	Time frame
Secondary end points are Serum 24,25-dihydroxycholecalciferol levels and Serum 3-epi-25-hydroxycholecalciferol levels.	—

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026